Engineered immune cells take on kidney disease in early trial
NCT ID NCT07241468
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment called anti-CD19/BCMA universal CAR T cells (KN3601) for people with relapsed or refractory immune-mediated kidney disease. The therapy involves collecting a patient's immune cells, engineering them to target and destroy harmful B cells, and infusing them back after a short chemotherapy course. The goal is to see if it is safe and can control the disease. About 36 adults aged 18-70 will participate.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anti-CD19/BCMA universal CAR T cells (KN3601)
- What this could lead to
- If successful, this could offer a new treatment option for people with hard-to-treat immune-mediated kidney disease, potentially controlling the disease without long-term medication.
- What could go wrong
- This is a very early (Phase 1) and small trial (36 people). CAR T therapy carries risks like severe immune reactions and infections. It may not work for all patients or may cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changhai Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug tame vasculitis with fewer side effects?
- Experimental drug aims to protect kidneys in inflammatory diseases
- Engineered immune cells take aim at autoimmune kidney diseases
- Could a diabetes drug shield kidneys from autoimmune attack?
- Scientists probe kidney cell metabolism to unlock secrets of ANCA vasculitis
- New tool could predict who will suffer from steroid side effects